Login to Your Account

Other News To Note

Wednesday, May 25, 2011
Marina Biotech Inc., of Bothell, Wash., reported data demonstrating increased hybridization affinity and activity with the company's Conformationally Restricted Nucleotide technology that ultimately could lead to the development of nucleic acid-based therapeutics for the treatment of cancers and other diseases. The company said the data were presented at TIDES Oligonucleotide and Peptide Research, Technology and Product Development in Boston

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription